Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
NexOptic Begins Announcing New Team Additions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Allakos Inc ALLK

Healthcare Biotechnology
Allakos Inc. is a clinical-stage biotechnology company. The Company is developing therapeutics, which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory, and proliferative diseases. Its advanced antibodies are lirentelimab (AK002) and AK006. AK002 selectively targets both mast cells and eosinophils, two types of white blood cells that are... see more

Recent & Breaking News (NDAQ:ALLK)

Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results

GlobeNewswire November 13, 2023

Allakos Appoints Neil Graham to its Board of Directors

GlobeNewswire August 30, 2023

Allakos Provides Business Update and Reports Second Quarter 2023 Financial Results

GlobeNewswire August 9, 2023

Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors

GlobeNewswire August 2, 2023

Allakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell Inhibition

GlobeNewswire June 12, 2023

Allakos Announces Upcoming Presentation on Lirentelimab and AK006 Mast Cell Inhibition at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023

GlobeNewswire June 5, 2023

Allakos Provides Business Update and Reports First Quarter 2023 Financial Results

GlobeNewswire May 9, 2023

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

GlobeNewswire March 6, 2023

Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications Biology

GlobeNewswire November 29, 2022

Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Society for Immunotherapy of Cancer's 37th Annual Meeting

GlobeNewswire November 10, 2022

Allakos Provides Business Update and Reports Third Quarter 2022 Financial Results

GlobeNewswire November 7, 2022

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire October 25, 2022

Allakos Announces Pricing of $150 Million Underwritten Offering of Common Stock

GlobeNewswire September 19, 2022

Allakos Announces Initiation of Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic Spontaneous Urticaria (CSU)

GlobeNewswire September 12, 2022

Allakos Announces Topline Phase 3 Data from the EoDyssey Study in Patients with Eosinophilic Duodenitis

GlobeNewswire September 9, 2022

Allakos Provides Business Update and Reports Second Quarter 2022 Financial Results

GlobeNewswire August 4, 2022

Allakos Announces the Appointment of Dr. Amy Ladd to its Board of Directors

GlobeNewswire July 25, 2022

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces Investigation of Breaches of Fiduciary Duties by Management of Allakos Inc.- ALLK

Newsfile June 15, 2022

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces Investigation of Breaches of Fiduciary Duties by Management of Allakos Inc.- ALLK

Newsfile June 14, 2022

INVESTIGATION NOTICE: The Schall Law Firm Announces Investigation of Breaches of Fiduciary Duties by Management of Allakos Inc.- ALLK

Newsfile June 13, 2022